Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with
- PDF / 663,780 Bytes
- 6 Pages / 594 x 792 pts Page_size
- 36 Downloads / 168 Views
18
Bulletin of Experimental Biology and Medicine, Vol. 169, No. 1, May, 2020 GENERAL PATHOLOGY AND PATHOPHYSIOLOGY
Experimental Study of Heart Functionality during Treatment of Chronic Heart Failure in Rats of Different Age Groups with Levosimendan (Experimental Study) M. L. Mamalyga and L. M. Mamalyga
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 169, No. 1, pp. 22-27, January, 2020 Original article submitted February 26, 2019 Levosimendan is effective in the therapy of chronic heart failure in both mature and old rats, but the duration of its therapeutic effect differs in these age groups. In 15 days after treatment, the myocardium in old rats maintained augmented functionality, whereas in old animals, functional potencies returned to the levels observed prior to the therapy. Stimulation of tissue respiration with combined administration of L-carnitine and α-lipoic acid against the background of levosimendan treatment prolonged its therapeutic effect in mature, but not in old rats. Key Words: chronic heart failure; levosimendan; ECG; heart functionality; tissue respiration Despite the development and adoption of novel and highly effective drugs, up to 50% old patients with severe forms of chronic heart failure (CHF) die during the first year after exacerbation of this disease; 60% of these patients die of sudden cardiac death [11,15]. In most cases, aggravation of CHF is determined by the age-related peculiarities of cardiac function. According to the modern paradigm of the heart aging, specific functional abnormalities develop in aging myocardium even in the absence of cardiovascular diseases, due to accumulation of molecular and structural alterations in cardiomyocytes impairing the contractile and relaxation processes, which elevates the risk of heart failure [4,7,8,15]. This suggests that the age-related myocardial rearrangements can affect not only treatment effectiveness, but also the duration of the therapeutic effect. In view of wide spread of cardiovascular diseases among people of different age and general trend of population aging in developed countries, the study of the peculiarities of CHF treatment in various age groups is an urgent problem of cardiology. LevosimenDepartment of Anatomy and Physiology of Humans and Animals, Institute of Biology and Chemistry, Moscow State Pedagogical University, Moscow, Russia. Address for correspondence: mamalyga_49@ mail.ru M. L. Mamalyga
dan (LS), a non-glycoside inotropic cardiac stimulant developed for the therapy of heart failure of different severity and etiology, is a promising drug widely used in cardiology [6,10,13]. Despite vigorous studies of its action in cardiac diseases, the influence of age-related peculiarities of the heart condition on the duration of the therapeutic effect of LS in CHF patients remains far from being solved. This work was designed to study functional potencies of the heart in LS-treated CHF rats at different ages and the duration of the therapeutic effects of this drug in mature and old animals.
MATER
Data Loading...
